Jiangsu Hengrui Medicine Co., Ltd., commonly known as Hengrui Medicine, is a prominent pharmaceutical company based in China. Established in 1970 and headquartered in Lianyungang, Jiangsu Province, the company has emerged as a key player in the global pharmaceutical industry.

Hengrui Medicine focuses on research, development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products. One of their core areas of expertise lies in the field of oncology, where they have made significant advancements in developing anti-tumor drugs to combat various types of cancer.

Beyond oncology, Hengrui Medicine is actively involved in producing medications for other therapeutic areas, including anti-infective drugs, cardiovascular drugs, and treatments for central nervous system disorders. Their commitment to research and innovation has been instrumental in expanding their product offerings and reaching patients in need.

Over the years, Hengrui Medicine has gained international recognition for its dedication to scientific excellence and adherence to strict quality standards. Their pursuit of cutting-edge research and collaboration with renowned pharmaceutical companies and research institutions has helped them establish a global presence.

Founded: 1997

Headquarters: Jiangsu, China

Website: https://www.hengrui.com/en/about.html

BeiGene Ltd. is a biopharmaceutical company headquartered in Beijing, China, with a global presence. Founded in 2010, BeiGene focuses on the discovery, development, manufacturing, and commercialization of innovative medicines, with a particular emphasis on oncology and immunology.

The company is committed to advancing cutting-edge science to address unmet medical needs and improve the lives of patients worldwide. BeiGene has built a robust pipeline of potential therapies, including small molecules, monoclonal antibodies, and cell therapies, targeting a wide range of cancers and autoimmune diseases.

BeiGene has been actively involved in clinical trials and research collaborations, working with leading academic institutions and other pharmaceutical companies to accelerate the development of novel treatments. Their dedication to scientific excellence has earned them recognition in the pharmaceutical industry.

The company's first commercialized product was zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, which received regulatory approval in several countries for the treatment of certain lymphomas. They have continued to expand their portfolio of approved products and investigational drugs, with a focus on precision medicine and personalized treatments.

Founded: 2010
Headquarters: Beijing, China
Website: https://www.beigene.com/

Shanghai Pharmaceuticals Holding Co., Ltd., commonly known as Shanghai Pharma, is a major Chinese pharmaceutical company headquartered in Shanghai, China. Established in 1994, the company operates in various segments of the pharmaceutical industry, including research, development, manufacturing, distribution, and retail.

Shanghai Pharma is involved in the production and distribution of a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, vaccines, traditional Chinese medicines, and medical devices. The company has a diverse portfolio of products that cater to various therapeutic areas and healthcare needs.

One of the key strengths of Shanghai Pharma lies in its distribution network. The company has an extensive distribution and retail network of pharmacies and drugstores across China. This widespread presence enables them to efficiently supply pharmaceutical products to consumers and healthcare institutions throughout the country.

Beyond the domestic market, Shanghai Pharma has also been expanding its international presence through acquisitions, collaborations, and partnerships. They have ventured into various global markets, strengthening their position in the global pharmaceutical industry.

Shanghai Pharma is committed to research and development, aiming to bring innovative treatments to the market. They actively engage in collaborations with research institutions and other pharmaceutical companies to advance their pipeline of potential therapies.

Founded: 1994
Headquarters: Shanghai, China
Website: https://www.sphbio.com/view/home/home.html

Fosun Pharmaceutical (Group) Co., Ltd. is a subsidiary of Fosun International Limited and is a major pharmaceutical company based in China. Fosun Pharma, as it is commonly known, was founded in 1994 and is headquartered in Shanghai, China. The company is engaged in various aspects of the pharmaceutical industry, including research, development, manufacturing, distribution, and commercialization of pharmaceutical and healthcare products.

Fosun Pharma has a diverse portfolio of products that cover a wide range of therapeutic areas, including oncology, cardiovascular diseases, central nervous system disorders, infectious diseases, and more. They are actively involved in developing both innovative and generic medications to cater to various healthcare needs.

The company has been actively expanding its global presence through strategic investments, acquisitions, and partnerships with international pharmaceutical companies. This expansion allows Fosun Pharma to access new markets and technologies, contributing to their growth and competitiveness on the global stage.

Fosun Pharma is also involved in the production and distribution of vaccines, medical devices, and diagnostic products, further diversifying its healthcare offerings.

As a part of Fosun International, Fosun Pharma operates in alignment with its parent company's global vision, which includes focusing on healthcare, finance, and other key sectors. The company's commitment to research and development and its pursuit of international collaborations have been significant drivers of its success in the pharmaceutical industry.

Founded: 1994

Headquarters: Shanghai, China

Website: https://www.fosunpharma.com/en/

CSPC Pharmaceutical Group Limited, commonly known as CSPC Pharma, is a leading Chinese pharmaceutical company with a diverse portfolio of products and a strong presence in both domestic and international markets. Founded in 1997, the company is headquartered in Shijiazhuang, Hebei Province, China.

CSPC Pharma is primarily engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Their product offerings include generic drugs, innovative drugs, and other healthcare products, covering various therapeutic areas such as anti-infective drugs, cardiovascular drugs, central nervous system medications, oncology treatments, and more.

The company has a strong commitment to research and development, investing significantly in innovative drug development to bring new and effective treatments to patients. Additionally, CSPC Pharma has a well-established manufacturing infrastructure, ensuring the high-quality production of their medications.

CSPC Pharma has been actively expanding its international footprint, exporting its products to different countries and regions around the world. This internationalization strategy has contributed to the company's growth and global recognition in the pharmaceutical industry.

In addition to its pharmaceutical business, CSPC Pharma is also involved in other healthcare-related areas, including the production and distribution of nutritional supplements and veterinary drugs.

Founded: 1997
Headquarters: Shijiazhuang, Hebei Province, China
Website: https://www.cspc.com.hk/

Sino Biopharmaceutical Limited, commonly known as Sino Biopharm, is a prominent Chinese biopharmaceutical company with a strong focus on research, development, manufacturing, and commercialization of pharmaceutical products. The company was founded in 2000 and is headquartered in Hong Kong.

Sino Biopharm is engaged in the production and distribution of a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and healthcare products. They have a diverse portfolio of medicines covering various therapeutic areas, including oncology, anti-infective drugs, gastrointestinal disorders, and more.

The company places a significant emphasis on research and innovation, investing in the development of novel treatments to address unmet medical needs. They collaborate with research institutions and other pharmaceutical companies to advance their pipeline of potential therapies.

One of Sino Biopharm's key strengths lies in its production capabilities, with modern and well-equipped manufacturing facilities. This allows them to produce high-quality pharmaceutical products that meet international standards.

Sino Biopharmaceutical has expanded its presence both in China and internationally, exporting its products to different countries and regions. Their international partnerships and collaborations have further strengthened their position in the global biopharmaceutical market.

Founded: 2000

Headquarters: Hong Kong

Website: https://www.sinobiopharm.com/en/

WuXi AppTec Co., Ltd. is a leading global pharmaceutical and biotechnology outsourcing company based in China. Founded in 2000, the company is headquartered in Shanghai and has a significant presence in various cities across China and worldwide.

WuXi AppTec provides a wide range of services to support the pharmaceutical, biotechnology, and medical device industries throughout the drug development and research process. Their services include contract research, development, and manufacturing (CRDM) services, analytical and testing services, bioanalytical services, drug screening and discovery, and preclinical and clinical development services.

The company operates state-of-the-art facilities and laboratories equipped with advanced technologies, enabling them to offer comprehensive solutions to their clients. WuXi AppTec's integrated platform allows for efficient and seamless collaboration, helping their clients accelerate drug development timelines and reduce costs.

WuXi AppTec has established strong partnerships and collaborations with numerous global pharmaceutical and biotechnology companies, academic institutions, and research organizations. Their reputation for delivering high-quality services and their expertise in various therapeutic areas have made them a preferred choice for outsourcing research and development activities.

In addition to their services in drug discovery and development, WuXi AppTec has also ventured into cell and gene therapies, providing specialized support for cutting-edge treatments in this rapidly advancing field.

Founded: 2000

Headquarters: Shanghai, China

Website: https://www.wuxiapptec.com/

China Resources Pharmaceutical Group Limited, also known as CR Pharmaceutical, is a major Chinese pharmaceutical company with a diverse range of healthcare products and services. The company is a subsidiary of China Resources Corporation, a large state-owned conglomerate. CR Pharmaceutical was established in 2003 and is headquartered in Beijing, China.

CR Pharmaceutical is involved in various aspects of the pharmaceutical industry, including research, development, manufacturing, marketing, and distribution of pharmaceutical products and medical devices. They have a broad portfolio of products that cover multiple therapeutic areas, such as cardiovascular, central nervous system, anti-infective, and gastrointestinal medications, among others.

The company has a strong focus on research and development, investing in innovative drug development to address unmet medical needs. They collaborate with leading research institutions and international pharmaceutical companies to advance their pipeline of potential therapies.

In addition to pharmaceuticals, CR Pharmaceutical also provides healthcare services, operates retail pharmacy chains, and offers medical insurance services. Their integrated healthcare approach aims to provide comprehensive solutions to meet the evolving needs of the healthcare industry in China.

Founded: 2003

Headquarters: Beijing, China

Website: https://www.crpharm.com/EN/

Zhejiang NHU Co., Ltd., commonly known as NHU, is a leading Chinese company engaged in the production and supply of fine chemicals and specialty chemicals. Founded in 1995, NHU is headquartered in Zhejiang Province, China.

NHU's business activities are primarily focused on three major areas: pharmaceutical intermediates, performance materials, and flavors and fragrances. The company manufactures and supplies a wide range of chemicals that find applications in various industries, including pharmaceuticals, food and beverages, cosmetics, and other industrial sectors.

In the pharmaceutical intermediates segment, NHU produces and supplies key ingredients used in the synthesis of various drugs and medications. They play a crucial role in the pharmaceutical supply chain, providing essential building blocks for the pharmaceutical industry.

The performance materials segment includes the production of chemicals used in plastics, fibers, and other advanced materials. NHU's performance materials are used in various applications, contributing to the enhancement of material properties and performance.

In the flavors and fragrances segment, NHU manufactures ingredients and additives used in the food and beverage, cosmetics, and personal care industries. Their products add taste, aroma, and sensory experiences to a wide range of consumer products.

NHU is committed to research and development, investing in innovation and technology to improve the quality and efficiency of their chemical production processes. The company's dedication to sustainability and environmental protection is also reflected in their business practices.

Founded: 1999
Headquarters: Zhejiang Province, China
Website: https://www.cnhu.com/en

Zhejiang Hisun Pharmaceutical Co., Ltd., commonly known as Hisun Pharma, is a major Chinese pharmaceutical company that specializes in the research, development, manufacturing, and distribution of pharmaceutical products. Founded in 1956, the company is headquartered in Taizhou, Zhejiang Province, China.

Hisun Pharma has a diverse portfolio of products, including both generic and innovative medications. They cover a wide range of therapeutic areas, such as cardiovascular diseases, anti-infective drugs, oncology treatments, central nervous system medications, and more.

The company places a strong emphasis on research and innovation, investing significantly in drug development to bring new and effective treatments to patients. They collaborate with research institutions, universities, and other pharmaceutical companies to advance their pipeline of potential therapies.

Hisun Pharma has a well-established manufacturing infrastructure and quality control systems to ensure the production of high-quality pharmaceutical products that meet international standards.

In addition to its pharmaceutical business, Hisun Pharma is also involved in the production and distribution of veterinary drugs, medical devices, and active pharmaceutical ingredients (APIs).

Hisun Pharma has been expanding its global presence through international partnerships, collaborations, and exportation of its products to various countries and regions around the world.

Founded: 1956

Headquarters: Taizhou, Zhejiang Province, China

Website: https://www.hisunpharm.com/en/

Sinopharm Group Co., Ltd., also known as China National Pharmaceutical Group Corporation, is one of the largest and most prominent state-owned pharmaceutical companies in China. It was established in 1998 and is headquartered in Beijing, China. Sinopharm is involved in various aspects of the pharmaceutical industry, including research, development, manufacturing, distribution, and retail.

The company's business spans a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, vaccines, traditional Chinese medicines, and medical devices. Sinopharm has a robust presence in the Chinese healthcare market and plays a crucial role in supplying essential medications and vaccines to meet the country's healthcare needs.

Sinopharm has also made significant contributions to global health, especially during the COVID-19 pandemic. The company has been actively involved in the production and distribution of COVID-19 vaccines, including inactivated virus vaccines. Their efforts have played a critical role in vaccination campaigns both within China and in other countries.

In addition to its pharmaceutical business, Sinopharm operates a chain of retail pharmacies, offering pharmaceutical and healthcare products directly to consumers. This retail segment further strengthens the company's position in the healthcare industry.

As a state-owned enterprise, Sinopharm Group operates under the guidance and policies of the Chinese government, and its activities align with national healthcare priorities and initiatives.

Founded: 2003

Headquarters: Sinopharm Plaza, Shanghai, China

Website: http://ir.sinopharmgroup.com.cn/html/index.php